EGFR-IN-32
EGFR-IN-32 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-32 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185297A1, compound 2) [1].
Product Specifications
CAS Number
2701553-78-6
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/egfr-in-32.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CC(NC2=NC=CC(C3=C(OC4=CC=CC=C4)C=CC=C3)=N2)=C(C=C1N(CCN(C)C)C)OC)C=C
Molecular Formula
C31H34N6O3
Molecular Weight
538.64
References & Citations
[1]Hongdao Chen, et al. Egfr tyrosine kinase inhibitors and their uses. Patent WO2021185297A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
BDNF Polyclonal Antibody, RBITC Conjugated
Carnitine Palmitoyltransferase 2, Mitochondrial (CPT2) Antibody
Carnitine Palmitoyltransferase 2, Mitochondrial (CPT2) Antibody
